CMV Dextramer assay
Detecting CMV-specific immunity

Cytomegalovirus (CMV) infects and establishes persistent lifelong infection in 60-90% of adults. Reactivation of the virus is a frequently occurring complication of immunosuppression, e.g. following transplantation, and can significantly contribute to morbidity and mortality in such patients. The presence of CD8+ T cells are important for controlling CMV infection and sufficiently low numbers of CMV-specific CD8+ T cells are predictive for development of CMV related complications in transplantation patients.  

CMV Dextramer Package
Immudex has developed a CMV Dextramer assay that can accurately detect and quantify CMV-specific T cells in blood samples. The assay panel consists of 8 MHC Dextramers comprising well characterized epitopes derived from the CMV proteins pp65 and IE1 and a negative control Dextramer.

Features and benefits: Accurate detection of CMV-specific T cells Clear interpretation of results High Population coverage (96% in Europe and USA) High stability High reproducibility Specific and sensitive detection	CMV Dextramer panel A*0101 (VTEHDTLLY) A*0201 (NLVPMVATV) A*0301 (KLGGALQAK) A*2402 (QYDPVAALF) B*0702 (RPHERNGFTVL) B*0702 (TPRVTGGGAM) B*0801 (ELRRKMMYM) B*3501 (IPSINVHHY) Negative control
	Bright staining and low background allow easy enumeration of CMV-specific T cells. Whole blood from CMV+ and HLA-A*0101 positive donor were stained with the HLA-A*0101 (VTEHDILLY) Dextramer (A) and the negative control Dextramer (B) using a general staining procedure. Live lymphocytes, CD3+ cells are shown.

 

Terms & Conditions

Privacy Statement

Legal Notice and Disclaimer